



# Regulatory CD8<sup>+</sup> T cells induced by exposure to all-trans retinoic acid and TGF- $\beta$ suppress autoimmune diabetes

Minoru Kishi, Hisafumi Yasuda \*, Yasuhisa Abe, Hiroto Sasaki, Mami Shimizu, Takashi Arai, Yasuyo Okumachi, Hiroaki Moriyama, Kenta Hara, Koichi Yokono, Masao Nagata

Department of Internal and Geriatric Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

## ARTICLE INFO

### Article history:

Received 26 February 2010

Available online 3 March 2010

### Keywords:

Regulatory CD8<sup>+</sup> T cells

All-trans retinoic acid

TGF- $\beta$

Dendritic cells

8.3-NOD

Foxp3

## ABSTRACT

Antigen-specific regulatory CD4<sup>+</sup> T cells have been described but there are few reports on regulatory CD8<sup>+</sup> T cells. We generated islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)-specific regulatory CD8<sup>+</sup> T cells from 8.3-NOD transgenic mice. CD8<sup>+</sup> T cells from 8.3-NOD splenocytes were cultured with IGRP, splenic dendritic cells (SpDCs), TGF- $\beta$ , and all-trans retinoic acid (ATRA) for 5 days. CD8<sup>+</sup> T cells cultured with either IGRP alone or IGRP and SpDCs in the absence of TGF- $\beta$  and ATRA had low Foxp3<sup>+</sup> expression ( $1.7 \pm 0.9\%$  and  $3.2 \pm 4.5\%$ , respectively). In contrast, CD8<sup>+</sup> T cells induced by exposure to IGRP, SpDCs, TGF- $\beta$ , and ATRA showed the highest expression of Foxp3<sup>+</sup> in IGRP-reactive CD8<sup>+</sup> T cells ( $36.1 \pm 10.6\%$ ), which was approximately 40-fold increase compared with that before induction culture. CD25 expression on CD8<sup>+</sup> T cells cultured with IGRP, SpDCs, TGF- $\beta$ , and ATRA was only 7.42%, whereas CD103 expression was greater than 90%. These CD8<sup>+</sup> T cells suppressed the proliferation of diabetogenic CD8<sup>+</sup> T cells from 8.3-NOD splenocytes *in vitro* and completely prevented diabetes onset in NOD-scid mice in cotransfer experiments with diabetogenic splenocytes from NOD mice *in vivo*. Here we show that exposure to ATRA and TGF- $\beta$  induces CD8<sup>+</sup>Foxp3<sup>+</sup> T cells *ex vivo*, which suppress diabetogenic T cells *in vitro* and *in vivo*.

© 2010 Elsevier Inc. All rights reserved.

## 1. Introduction

The adaptive immune response is initiated by T cells that express receptors for diverse antigens. The repertoire of T cell receptors is regulated by positive selection and negative selection. Autoreactive T cells are usually deleted by negative selection in the thymus [1]. However this process is not exhaustive: T cells expressing receptors with low affinities for self-antigens are usually present in peripheral organs and may cause autoimmune disease if activated. Suppressor mechanisms for self-reactive T cells in peripheral organs have been presumed. The concept of T cell suppression of the immune response was first proposed by Gershon and Kondo for regulatory CD8<sup>+</sup> T cells [2]. There are few studies on regulatory CD8<sup>+</sup> T cells because of the difficulty of identifying regulatory CD8<sup>+</sup> T cell populations and their mechanisms of action. The CD4<sup>+</sup> population of regulatory T cells (Tregs) was first described by Sakaguchi et al. as CD4<sup>+</sup>CD25<sup>+</sup> T cells [3]. Although CD25 expression has been used as a marker to identify Tregs, it is not specific for Tregs because it is expressed by all activated T cells. Recent studies revealed that the forkhead/winged helix family (Foxp3) transcription factor is a master switch specific to

CD4<sup>+</sup>CD25<sup>+</sup> Tregs that induces differentiation of naive T cells into the Treg lineage and maintains their suppressive function [4,5].

The CD4<sup>+</sup>CD25<sup>+</sup> T cells described by Sakaguchi et al. originated in the thymus and developed their suppressive function in peripheral organs. On the other hand, Luo et al. revealed that transforming growth factor- $\beta$  (TGF- $\beta$ ) and  $\beta$ -cell peptide-pulsed dendritic cells from NOD mice induced CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells from naive T cells in BDC2.5-NOD splenocytes, which suppressed diabetes onset in cotransfer experiments [6]. In contrast to the regulatory cells in the thymus, BDC2.5 CD4<sup>+</sup>CD25<sup>+</sup> T cells can be switched to CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells by regulatory cytokines such as TGF- $\beta$ .

Vitamin A (retinol) and its metabolites (retinoids) are a group of potent natural or synthetic molecules which act as modulators for a variety of inflammatory and immunological events in immune system. The mechanism of this molecule has been reported as suppression of inflammatory immune cells, modulation of the function of immune cells and production of several cytokines [7]. All-trans retinoic acid (ATRA), a potent retinoid, has been clinically used to treat acute leukaemia and acne vulgaris [8,9]. Now it has also been reported as having a potential of generating CD4<sup>+</sup> Tregs [10,11]. In addition, dendritic cells purified from the small intestine were found to undergo a high level of CD4<sup>+</sup> Treg conversion when exposed to TGF- $\beta$  and ATRA that was highly expressed in GALT [12].

\* Corresponding author. Fax: +81 78 382 5919.

E-mail address: [yasuda@med.kobe-u.ac.jp](mailto:yasuda@med.kobe-u.ac.jp) (H. Yasuda).

Recent publications have shown that the regulatory T cell family consists not only of CD4<sup>+</sup> T cells but also CD8<sup>+</sup> T cells [13–17], presuming that regulatory CD8<sup>+</sup> T cells can be induced from these naïve CD8<sup>+</sup> T cells in 8.3-NOD mice in an adequate milieu. In this study, we generated regulatory CD8<sup>+</sup> T cells from transgenic 8.3-NOD mice expressing CD8-TCR specific for islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) in  $\beta$ -cells [18]. CD8<sup>+</sup> T cells exposed to ATRA and TGF- $\beta$  exhibited regulatory functions *in vitro* and *in vivo*.

## 2. Materials and methods

### 2.1. Mice

NOD/Shi/Kbe mice were maintained at the Institute for Experimental Animals, Kobe University School of Medicine, Kobe, Japan. The cumulative incidence of diabetes is 85% in females and 30% in males at 40 weeks of age. NOD-scid mice were purchased from Clea Japan (Osaka, Japan). 8.3-NOD mice were purchased from Jackson Laboratories (Bar Harbor, ME). All animals were treated according to the Guidelines for Animal Experimentation of Kobe University School of Medicine.

### 2.2. Antibodies and reagents

FITC-conjugated anti-mouse monoclonal antibodies, CD8 (53–6.7) and CD103 (M290), were purchased from Pharmingen (San Diego, CA), as were the phycoerythrin (PE)-conjugated anti-mouse monoclonal antibodies, CD4 (L3T4), CD8 (53–6.7), and B220 (RA3–6B2), peridinin chlorophyll protein complex (PerCP)-conjugated anti-mouse CD4 monoclonal antibody (L3T4), and the APC-conjugated anti-mouse CD25 monoclonal antibody (3C7). The PE-conjugated anti-mouse Foxp3 monoclonal antibody (FJK-16s) was purchased from eBioscience (San Diego, CA). Anti-CD11c (N418) microbeads and the CD8 isolation kit were purchased from Miltenyi Biotec (Bergisch-Gladbach, Germany). Carboxyfluorescein diacetate succinimidyl ester (CFSE) was purchased from Dojindo (Kumamoto, Japan).

### 2.3. Cell purification and culture

Splenic dendritic cells (SpDCs) were purified from 8- to 12-week-old 8.3-NOD mice splenocytes using CD11c-magnetic beads. After selection using an autoMACS magnetic cell sorter (Miltenyi Biotec), CD8<sup>+</sup> T cells were purified by depletion of CD4-, B220-, CD49b-, CD11b-, and Ter-119-positive cells. To study the proliferation of CD8<sup>+</sup> T cells, some cells were stained with 10  $\mu$ M CFSE for 15 min at 37 °C followed by two washes with HBSS at 4 °C. All cells were cultured in an atmosphere containing 5% CO<sub>2</sub> at 37 °C in 96-well tissue culture plates in 200  $\mu$ l of RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM sodium pyruvate, 10 mM Hepes buffer, 50 IU/ml penicillin, 50  $\mu$ g/ml streptomycin, 40  $\mu$ g/ml gentamycin and  $5 \times 10^{-5}$  M 2-mercaptoethanol. CD8<sup>+</sup> T cells ( $6.0 \times 10^4$ ) were cultured with 0.1  $\mu$ M of IGRP alone or with IGRP and  $2.0 \times 10^4$  of SpDCs as controls. In addition to IGRP and SpDCs, CD8<sup>+</sup> T cells in other groups were cultured with 2 ng/ml of TGF- $\beta$  or with TGF- $\beta$  and 10 nM of ATRA to induce the regulatory cells. Five days later, cells were harvested and stained with several antibodies and propidium iodide (PI); only PI-negative cells were analyzed using the FACS 440 flow cytometer (Becton Dickinson, San Jose, CA). For each group, the CD8<sup>+</sup> T cells were cultured as described previously and harvested; only CD8<sup>+</sup> T cells were selected using the magnetic beads. CD8<sup>+</sup> T cells cultured with IGRP alone were designated I cells, those cultured with IGRP and SpDCs were designated ID cells, those cultured with IGRP, SpDCs, and TGF- $\beta$  were

designated IDT cells, and those cultured with IGRP, SpDCs, TGF- $\beta$ , and ATRA were designated IDTA cells.

### 2.4. Proliferation assays

CD8<sup>+</sup> T cells from 8.3-NOD splenocytes that were selected using magnetic beads were stained with 10  $\mu$ M CFSE for 15 min at 37 °C and were washed twice. Induced CD8<sup>+</sup> T cells ( $1.0 \times 10^5$ ) (I cells, ID cells, IDT cells, or IDTA cells) and CFSE-stained fresh CD8<sup>+</sup> T cells ( $1.0 \times 10^5$ ) were cultured together with 0.1  $\mu$ M of IGRP. After 3 days, all cells were harvested and only CFSE<sup>+</sup> cells were analyzed using flow cytometry. To further examine the suppressor activity of induced CD8<sup>+</sup> T cells *in vitro*, freshly-isolated effector CD8<sup>+</sup> T cells ( $1.0 \times 10^5$ ) (E) were cultured with induced CD8<sup>+</sup> T cells (IDT cells or IDTA cells) (R) at the indicated ratios in the presence of 0.1  $\mu$ M of IGRP.

### 2.5. Adoptive transfer

CD8<sup>+</sup> T cells ( $6.0 \times 10^6$ ) from 8.3-NOD splenocytes cultured with IGRP alone or IGRP, SpDCs, TGF- $\beta$ , and ATRA were intravenously cotransferred into 8-week-old NOD-scid mice with  $1 \times 10^7$  diabetogenic NOD splenocytes. The recipients were monitored for diabetes onset by testing urine glucose level twice weekly. Diabetes was defined as a blood glucose concentration greater than 250 mg/dl (13.9 mmol/l) on two consecutive days.

### 2.6. Statistical analysis


Statistical analysis of the incidence of diabetes was performed using the log-rank test. Statistical analyses of flow cytometric data were performed using the Mann-Whitney *U* test. A *p* value less than 0.05 was considered significant. All data are presented as the means  $\pm$  SD.

## 3. Results

### 3.1. Induction of CD8<sup>+</sup>Foxp3<sup>+</sup> T cells from splenocytes in 8.3-NOD mice

The prevalence of CD8<sup>+</sup>Foxp3<sup>+</sup> T cells among splenocytes in 7-week-old 8.3-NOD mice was first analyzed using flow cytometry to evaluate “natural” CD8<sup>+</sup>Foxp3<sup>+</sup> T cells. The population of CD8<sup>+</sup> T cells in the spleen from 8.3-NOD mice exceeded 50% of splenocytes, which was higher than that of littermate NOD mice (Fig. 1A). The population of CD8<sup>+</sup>Foxp3<sup>+</sup> T cells in the spleen from 8.3-NOD mice was no more than 1.0% of splenocytes, which was equal to that in littermate NOD mice (Fig. 1B).

SpDCs and CD8<sup>+</sup> T cells were cultured for inducing regulatory CD8<sup>+</sup> T cells *ex vivo*. SpDCs were selected from the splenocytes of 8.3-NOD mice using CD11c-magnetic beads. CD8<sup>+</sup> T cells were negatively selected using magnetic beads followed by labeling with CFSE. CFSE-labeled CD8<sup>+</sup> T cells ( $6.0 \times 10^4$ ) were cultured for 5 days with 0.1  $\mu$ M of IGRP alone (I cells), IGRP and  $2.0 \times 10^4$  SpDCs (ID cells), IGRP, SpDCs, and 2 ng/ml of TGF- $\beta$  (IDT cells) or with IGRP, SpDCs, TGF- $\beta$ , and 10 nM of ATRA (IDTA cells). Fig. 1C and D show the *in vitro* proliferation of Foxp3<sup>+</sup> cells in cultured CD8<sup>+</sup> T cells from 8.3-NOD splenocytes. Only  $1.7 \pm 0.9\%$  of I cells and  $3.2 \pm 4.5\%$  of ID cells expressed Foxp3, whereas  $8.6 \pm 6.7\%$  of IDT cells and  $21.4 \pm 4.2\%$  of IDTA cells expressed Foxp3. IDTA cells showed the highest expression of Foxp3 and significantly higher expression than I cells ( $p = 0.028$ ). To further examine whether the efficiency of conversion to Tregs can be increased, we also cultured CD8<sup>+</sup> T cells from 8.3-NOD mice with titrating concentrations of ATRA (0, 1, 5, 10, and 20 nM) in the presence of constant IGRP, splenic DC, and TGF- $\beta$  concentrations. The percentage of Foxp3<sup>+</sup>



**Fig. 1.** (A, B) Splenocytes from 7-week-old 8.3-NOD or NOD mice were stained with anti-CD4 and CD8 antibodies (A) or anti-Foxp3 and CD8 antibodies (B). A representative example of four separate experiments is shown. (C, D, E) CFSE-labeled CD8<sup>+</sup> T cells ( $6.0 \times 10^4$ ) selected from the splenocytes of 7-week-old 8.3-NOD mice were cultured for 5 days with 0.1  $\mu$ M of IGRP alone (I cells), IGRP and  $2.0 \times 10^4$  SpDCs (ID cells), IGRP, SpDCs, and 2 ng/ml of TGF- $\beta$  (IDT cells), or IGRP, SpDCs, TGF- $\beta$ , and 10 nM of ATRA (IDTA cells). Five days later, all cells were harvested and gated on PI-negative and CFSE positive cells. A representative example (C), percentage of Foxp3<sup>+</sup> cells in CFSE<sup>+</sup> cells ( $p = 0.028$ , I vs. IDTA) (D) and percentage of Foxp3<sup>+</sup> cells in IGRP-reactive CFSE<sup>+</sup> cells ( $p = 0.048$ , I vs. IDTA) (E) are shown.

cells in 10 nM of ATRA was the highest among these titrating concentrations (data not shown). Among IGRP-responded CD8<sup>+</sup> T cells,  $36.1 \pm 10.6\%$  of IDTA cells showed Foxp3 expression, which was approximately 40-fold increase compared with that before induction culture and significantly higher than that of I cells ( $p = 0.048$ ) (Fig. 1E).

### 3.2. Cell surface marker of CD8<sup>+</sup>Foxp3<sup>+</sup> T cells

To determine which surface markers were expressed on CD8<sup>+</sup>Foxp3<sup>+</sup> T cells, IDT cells or IDTA cells were stained with CD25 and CD103 antibodies (Fig. 2). In contrast to CD4<sup>+</sup>Foxp3<sup>+</sup> T cells, only some of the CD8<sup>+</sup>Foxp3<sup>+</sup> T cells were CD25-positive, and most were CD103-positive.

### 3.3. In vitro suppression assay


To examine the suppressor activity of CD8<sup>+</sup> T cells *in vitro*,  $1.0 \times 10^5$  of the CFSE-labeled effector CD8<sup>+</sup> T cells were cultured with IGRP and  $1.0 \times 10^5$  of I, ID, IDT, or IDTA cells (Fig. 3A). Proliferation of CD8<sup>+</sup> T cells in the presence of I, ID, IDT, or IDTA cells with IGRP was compared with that induced by IGRP alone. % Suppression of each proliferation was  $-1.8 \pm 7.6\%$ ,  $2.9 \pm 9.0\%$ ,  $1.0 \pm 8.5\%$ , and  $12.9 \pm 8.9\%$ , respectively, and the presence of I, ID, or IDT cells did not markedly suppress proliferation of IGRP-reactive CD8<sup>+</sup> T cells. In addition, there was no significant suppression in the presence of ID cells or IDT cells compared with the presence of I cells ( $p > 0.05$ ). However, only the presence of IDTA cells significantly suppressed proliferation of IGRP-reactive effector CD8<sup>+</sup> T cells than the presence of I cells ( $p = 0.009$ ) (Fig. 3B). Furthermore, the suppressive activity seems to be strengthened in a E:R ratio-dependent manner, though not all of IDTA cells express Foxp3 (Fig. 3C).

### 3.4. In vivo suppression assay


Because IDTA cells alone have suppressor activity for diabetogenic antigen-specific CD8<sup>+</sup> T cells *in vitro*, *in vivo* suppressor activity was examined using a diabetes-transfer model. IDTA cells or I cells were intravenously transferred into NOD-scid mice with diabetogenic splenocytes from NOD mice. All of five mice injected with diabetogenic NOD splenocytes alone and six mice injected with diabetogenic splenocytes and I cells became diabetic by 44 days after transfer. In contrast, none of the five mice injected with diabetogenic splenocytes and IDTA cells became diabetic in this cotransfer experiment ( $p = 0.01$ , IDTA vs. control) (Fig. 4). In another set of experiment, none of mice injected with diabetogenic splenocytes and IDTA cells became diabetic even at 150 days after transfer which was more than 30 days after last positive control became diabetic (data not shown). These findings suggest that CD8<sup>+</sup> T cells induced by exposure to SpDCs, TGF- $\beta$ , and ATRA have suppressor activity against the autoimmune response *in vivo* and that the disease should be suppressed only by the Foxp3<sup>+</sup> population.

## 4. Discussion

This study demonstrates that regulatory CD8<sup>+</sup> T cells can be induced from diabetogenic 8.3 transgenic NOD mice, which express the TCR- $\alpha$  and TCR- $\beta$  of a diabetogenic H-2K<sub>d</sub>-restricted  $\beta$ -cell cytotoxic CD8<sup>+</sup> T cell clone and promote diabetes [19]. Original NY8.3 CD8<sup>+</sup> cloned T cells cause severe insulinitis and diabetes when cotransferred with NOD CD4<sup>+</sup> T cells [20]. The 8.3-NOD mice in our colony develop diabetes more rapidly than the original NOD mice, but the incidence of diabetes does not differ from that of NOD mice (75% among females aged 20 weeks and 30 weeks, respectively). Santamaria et al. reported that high avidity of 8.3 TCR T cells devel-



**Fig. 2.** IDT cells and IDTA cells were stained with antibodies against Foxp3, CD25, and CD103. Only some of the CD8<sup>+</sup>Foxp3<sup>+</sup> T cells were CD25-positive, and most were CD103-positive. A representative example of four separate experiments is shown.




**Fig. 3.** CFSE-labeled CD8<sup>+</sup> T cells ( $1.0 \times 10^5$ ) purified from 8.3-NOD splenocytes were cultured for 5 days with IGRP alone or with IGRP and  $1.0 \times 10^5$  induced CD8<sup>+</sup> T cells in each group shown in Fig. 1. Three days later, all cells were harvested and gated on CFSE<sup>+</sup> cells. (A) Proliferation of CD8<sup>+</sup> T cells induced by IGRP alone or in the presence of I, ID, IDT, or IDTA cells with IGRP was examined. A representative example of eight separate experiments is shown. (B) Proliferation of effector CD8<sup>+</sup> T cells in the presence of I, ID, IDT, or IDTA cells with IGRP was shown as % suppression, in comparison with that induced by IGRP alone ( $p = 0.009$ , I vs. IDTA). (C) Proliferation of effector CD8<sup>+</sup> T cells (E) in the presence of IDT, or IDTA cells (R) with IGRP in comparison with that induced by IGRP alone was shown as % suppression at the indicated E:R ratios.

ops with aging in 8.3-NOD mice [21]. Because 10–20% of the mice did not develop diabetes, we presumed that regulatory T cells were present in 8.3-NOD mice. We generated Tregs in CD8<sup>+</sup> T cells for this reason.

Induced regulatory CD8<sup>+</sup> T cells have been used in some studies [14–17], two of which showed that Foxp3 is an important marker of regulatory CD8<sup>+</sup> T cells [14,17]. Regulatory CD8<sup>+</sup> T cells cultured

with IGRP, SpDCs, TGF-β, and ATRA showed suppressor activity and the highest expression of Foxp3, which indicates that CD8<sup>+</sup>Foxp3<sup>+</sup> T cells played a key role in the generation of regulatory CD8<sup>+</sup> T cells. Although the role of the expression of Foxp3 in these CD8<sup>+</sup> T cells is not well understood, Foxp3 expression is known to induce regulatory T cells. The Foxp3-transduced 6426 CD8<sup>+</sup> T cell clone, which recognizes insulin B chain peptide 15–23, delayed the





**Fig. 4.** Diabetogenic NOD splenocytes ( $1 \times 10^7$ ) alone (closed circle,  $n = 5$ ) or with  $6.0 \times 10^6$  I cells (open square,  $n = 6$ ) or IDTA cells (closed square,  $n = 5$ ) were transferred into 7- to 8-week-old NOD-scid mice. I cells had no effect on suppression of diabetes transfer, whereas IDTA cells completely suppressed diabetes transfer ( $p = 0.01$ , IDTA vs. control).

onset of diabetes compared with control 6426 clone when transferred into NOD-scid or young NOD mice [22]. This study indicated that expression of Foxp3 changes effector CD8<sup>+</sup> T cells into regulatory CD8<sup>+</sup> T cells.

Rigorous purification of regulatory CD8<sup>+</sup>Foxp3<sup>+</sup> T cells in cellular transfusion material would prevent autoimmune diabetes. Because Foxp3 is not a surface marker, we examined whether the CD8<sup>+</sup>Foxp3<sup>+</sup> T cells express specific surface markers that would enable purification of these cells *in vitro*. Unlike the case with CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> T cells, CD25 is not a marker of regulatory CD8<sup>+</sup> T cells. More than 90% of the CD8<sup>+</sup>Foxp3<sup>+</sup> T cells induced in our study also expressed CD103. CD103, the  $\alpha\text{E}\beta 7$  integrin, is a marker for alloantigen-induced regulatory CD8<sup>+</sup> T cells [15,23,24]. As CD8<sup>+</sup>Foxp3<sup>+</sup> T cells also expressed CD103, it is not completely specific for CD8<sup>+</sup>Foxp3<sup>+</sup> T cells. Purification of regulatory T cells using a CD103 antibody may isolate CD8<sup>+</sup>Foxp3<sup>+</sup> T cells more efficiently.

ATRA has been reported to play an important role in immune system so far. It has been currently used to treat acute leukaemia and acne vulgaris [8,9]. The role of ATRA in the generation of CD4<sup>+</sup> regulatory T cells has also been reported recently [10–12]. Belkaid et al. reported that naïve CD4<sup>+</sup>Foxp3<sup>+</sup> T cells converted CD4<sup>+</sup>Foxp3<sup>+</sup> T cells in the gut and that gut-resident DCs produced ATRA. This conversion of Tregs occurred in a TGF- $\beta$  and ATRA-dependent fashion [12]. Powrie et al. also reported that ATRA-dependent naïve T cells converted to Tregs after oral administration of antigen [11]. CD4<sup>+</sup>Foxp3<sup>+</sup> T cells cultured with TGF- $\beta$ , IL-2, and ATRA can convert into a CD4<sup>+</sup>Foxp3<sup>+</sup> $\alpha\text{E}\beta 7$ CCR9<sup>+</sup> phenotype *in vitro* and ATRA enhances the expression of Foxp3 and increases their suppressor activity [10]. ATRA can induce regulatory CD4<sup>+</sup> T cells from naïve CD4<sup>+</sup> T cells more efficiently in a Foxp3-dependent way. In this study, we first showed that ATRA and TGF- $\beta$  was used to generate regulatory CD8<sup>+</sup> T cells *ex vivo*.

## 5. Conclusions

ATRA and TGF- $\beta$  induce antigen-specific regulatory CD8<sup>+</sup> T cells in autoimmune diabetic mice. Regulatory CD8<sup>+</sup> T cells induced

*ex vivo* would be useful as a therapeutic tool for autoimmune diabetes.

## Acknowledgment

We are grateful to Ms. Atsumi Katsuta for her outstanding assistance.

## References

- [1] H. Hengartner, B. Odermatt, R. Schneider, et al., Deletion of self-reactive T cells before entry into the thymus medulla, *Nature* 336 (1988) 388–390.
- [2] R.K. Gershon, K. Kondo, Cell interactions in the induction of tolerance: the role of thymic lymphocytes, *Immunology* 18 (1970) 723–737.
- [3] S. Sakaguchi, N. Sakaguchi, M. Asano, et al., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor  $\alpha$ -chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases, *J. Immunol.* 155 (1995) 1151–1164.
- [4] S. Hori, T. Nomura, S. Sakaguchi, Control of regulatory T cell development by the transcription factor Foxp3, *Science* 299 (2003) 1057–1061.
- [5] J.D. Fontenot, M.A. Gavin, A.Y. Rudensky, Foxp3 programs the development and function of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells, *Nat. Immunol.* 4 (2003) 330–336.
- [6] X. Luo, K.V. Tarbell, M. Suthanthiran, et al., Dendritic cells with TGF- $\beta$ 1 differentiate naïve CD4<sup>+</sup>CD25<sup>+</sup> T cells into islet-protective Foxp3<sup>+</sup> regulatory T cells, *Proc. Natl. Acad. Sci. USA* 101 (2007) 2821–2826.
- [7] K. Pino Lagos, M.J. Benson, R.J. Noelle, Retinoic acid in the immune system, *Ann. NY Acad. Sci.* 1143 (2008) 170–187.
- [8] S. Castaigne, C. Chomienne, M.T. Daniel, et al., All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results, *Blood* 76 (1990) 1704–1709.
- [9] J.J. Leyden, Therapy for acne vulgaris, *N. Engl. J. Med.* 336 (1997) 1156–1162.
- [10] M.J. Benson, K. Pino Lagos, M. Roseblatt, et al., All-trans retinoic acid mediates enhanced Treg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation, *J. Exp. Med.* 204 (2007) 1765–1774.
- [11] J.L. Coombes, K.R. Siddiqui, C.V. Arancibia-Carcamo, et al., A functionally specialized population of mucosal CD103<sup>+</sup> DCs induces Foxp3<sup>+</sup> regulatory T cells via a TGF- $\beta$  and retinoic acid-dependent mechanism, *J. Exp. Med.* 204 (2007) 1757–1764.
- [12] C.M. Sun, J.A. Hall, R.B. Blank, et al., Small intestine lamina propria dendritic cells promote de novo generation of Foxp3<sup>+</sup> Treg cells via retinoic acid, *J. Exp. Med.* 204 (2007) 1775–1785.
- [13] M. Rifa'i, Y. Kawamoto, I. Nakashima, et al., Essential roles of CD8<sup>+</sup>CD122<sup>+</sup> regulatory T cells in the maintenance of T cell homeostasis, *J. Exp. Med.* 200 (2004) 1123–1134.
- [14] R.P. Singh, A. La Cava, M. Wong, et al., CD8<sup>+</sup> T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression, *J. Immunol.* 178 (2007) 7649–7657.
- [15] E. Uss, A.T. Rowshani, B. Hooibrink, et al., CD103 is a marker for alloantigen-induced regulatory CD8<sup>+</sup> T cells, *J. Immunol.* 177 (2006) 2775–2783.
- [16] S.D. Koch, E. Uss, R.A. van Lier, et al., Alloantigen-induced regulatory CD8<sup>+</sup>CD103<sup>+</sup> T cells, *Hum. Immunol.* 69 (2008) 737–744.
- [17] M. Mahic, K. Henjum, S. Yaqub, et al., Generation of highly suppressive adaptive CD8<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells by continuous antigen stimulation, *Eur. J. Immunol.* 38 (2008) 640–646.
- [18] S.M. Lieberman, A.M. Evans, B. Han, et al., Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8<sup>+</sup> T cells in autoimmune diabetes, *Proc. Natl. Acad. Sci. USA* 100 (2003) 8384–8388.
- [19] J. Verdaguer, J.W. Yoon, B. Anderson, et al., Acceleration of spontaneous diabetes in TCR-beta-transgenic nonobese diabetic mice by beta-cell cytotoxic CD8<sup>+</sup> T cells expressing identical endogenous TCR-alpha chains, *J. Immunol.* 157 (1996) 4726–4735.
- [20] M. Nagata, P. Santamaria, T. Kawamura, et al., Evidence for the role of CD8<sup>+</sup> cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice, *J. Immunol.* 152 (1994) 2042–2050.
- [21] A. Amrani, J. Verdaguer, P. Serra, et al., Progression of autoimmune diabetes driven by avidity maturation of a T-cell population, *Nature* 406 (2000) 739–742.
- [22] J. Peng, B. Dicker, W. Du, et al., Converting antigen-specific diabetogenic CD4 and CD8 T cells to TGF- $\beta$  producing non-pathogenic regulatory cells following FoxP3 transduction, *J. Autoimmun.* 28 (2007) 188–200.
- [23] J. Lehmann, J. Huehn, M. de la Rosa, et al., Expression of the integrin  $\alpha\text{E}\beta 7$  identifies unique subsets of CD25<sup>+</sup> as well as CD25<sup>+</sup> regulatory T cells, *Proc. Natl. Acad. Sci. USA* 99 (2002) 13031–13036.
- [24] A. Banz, A. Peixoto, C. Pontoux, et al., A unique subpopulation of CD4<sup>+</sup> regulatory T cells controls wasting disease, IL-10 secretion and T cell homeostasis, *Eur. J. Immunol.* 33 (2003) 2419–2428.